X

Trial Profile

An Open Label, Proof of Mechanism Study to Explore the Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 08 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BBT-401 (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Sponsors Bridge Biotherapeutics

Most Recent Events

27 Sep 2021 Status changed from recruiting to discontinued due to Internal Company Decision .
02 Aug 2021 Planned End Date changed from 30 Jun 2021 to 15 Jun 2022.
02 Aug 2021 Planned primary completion date changed from 30 Apr 2021 to 31 May 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com